¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Acute leukaemia of unspecified cell type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® acute hepatitis ÇÑ±Û ±Þ¼º°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼­ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, À̴ ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇϴ ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°À̸砳ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀ̠ã¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿­-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³­´Ù. µÚÀ̾î È²´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º­¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª È²´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â È²´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» Çصµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿­ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀ̠Ư¡À̸砱޼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º­¿î °ÍÀ̠Ư¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀΠ°ÍÀÌ º¸ÅëÀÌ´Ù.
¿µ¹® acute appendicitis ÇÑ±Û ±Þ¼º¸·Ã¢ÀÚ²¿¸®¿°
¼³¸í   
  ¿Ü°úÀû Ã³Ä¡¸¦ ¿äÇϴ ¸·Ã¢ÀÚ²¿¸®(Ãæ¼ö)ÀÇ ±Þ¼º¿°ÁõÀ¸·Î¼­, º¸Åë ÇϺ¹ºÎÀÇ ¿À¸¥ÂÊ 1/4 ºÎÀ§¿¡¼­ÀÇ ÅëÁõÀ̠Ư¡À̸ç, ±¹¼Ò¾ÐÅë, ±ÙÀ°±äÀå ÇǺΰ¨°¢ÀÇ °ú¹Î µîÀ» ¼ö¹ÝÇÑ´Ù. ÀϹݵòµéÀÌ ¡°¸ÍÀå¿°¡±À̶ó°í Çϴ °ÍÀ¸·Î ¸ÍÀå¿°Àº ¸·Ã¢ÀÚÀÇ ¿°ÁõÀ¸·Î ±¸º°µÇ¾î¾ß ÇÑ´Ù. ¹ß¿­°ú ´ÙÇü¹éÇ÷±¸Áõ´Ù´Â ±¹¼Ò°¨¿°ÀÇ °á°úÀÌ´Ù. ¸·Ã¢ÀÚ²¿¸®ÀÇ À§Ä¡-À¯Âø»óÅÂ-²¿ÀÓ µî¿¡ ÀÇÇØ Áõ»ó°ú Â¡ÈĴ º¯µ¿µÈ´Ù.
¿µ¹® acute cholecystitis ÇÑ±Û ±Þ¼º¾µ°³¿°
¼³¸í   
  º¸Åë ¾µ°³ ÃⱸÀÇ Æó»ö¿¡ ÀÇÇÑ °ÍÀ̸ç, ¿°ÁõÀÇ Á¤µµ´Â °æµµÀÇ ºÎÁ¾À¸·ÎºÎÅÍ ±«Àú¿Í Ãµ°øÀ» ¼ö¹ÝÇϴ °¨¿°Áõ±îÁö ÀÖ´Ù.
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û »ç½º
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. 
  
  
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼ºÈ£Èí±âº´À¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • enteropathy-type T-cell lymphoma
    À庴ÁõÇüT¼¼Æ÷¸²ÇÁÁ¾
  • asthenic type
    ¹«·ÂüÇü
  • blood type
    Ç÷¾×Çü
  • Borrmann type
    º¸¸£¸¸Çü
  • Cowdry type A inclusion bodies
    Ä«¿ìµå¸®AÇüÆ÷ÇÔü, Ä«¿ìµå¸®AÇüºÀÀÔü
  • Cowdry type B inclusion bodies
    Ä«¿ìµå¸®BÇüÆ÷ÇÔü, Ä«¿ìµå¸®BÇüºÀÀÔü
  • delayed-type hypersensitivity
    Áö¿¬°ú¹Î(¼º)
  • disorganized type schizophrenia
    ºØ±«ÇüÁ¤½ÅºÐ¿­º´
  • extroverted feeling type
    ¿ÜÇâÀû°¨Á¤Çü
  • extroverted type
    ¿ÜÇâÇü
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷, °ñÁö1Çü½Å°æ¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷, °ñÁö2Çü½Å°æ¼¼Æ÷
  • hyperlipidemia type I
    1Çü°íÁöÇ÷Áõ
  • hyperlipidemia type IV
    4Çü°íÁöÇ÷Áõ
  • hyperlipidemia type V
    5Çü°íÁöÇ÷Áõ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tension type headache
    ±äÀåÇüµÎÅë
  • storage-type
    ÃàÀûÇü
  • type
    Çü, À¯Çü
  • blood type
    Ç÷¾×Çü
  • Borrmann type
    º¸¸£¸¸Çü
  • cellular type
    ¼¼Æ÷Çü
  • lepromatous type
    ³ªÁ¾Çü
  • scirrhous type
    °æÈ­Çü
  • acute
    ±Þ¼º-
  • acute appendicitis
    ±Þ¼º¸·Ã¢ÀÚ²¿¸®¿°
  • acute pulmonary atelectasis
    ±Þ¼º¹«±âÆó
  • acute abdomen
    ±Þ¼ºº¹Áõ
  • acute cholecystitis
    ±Þ¼º¾µ°³¿°
  • acute acalculous cholecystitis
    ±Þ¼º¹«°á¼®¾µ°³¿°
  • acute emphysematous cholecystitis
    ±Þ¼º°ø±âÁõ¾µ°³¿°, ±Þ¼º°ø±âÁõ´ã³¶¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute
    ±Þ¼º-
  • acute exposure
    ±Þ¼ºÇÇÆø, ±Þ¼º³ëÃâ
  • acute abdomen
    ±Þ¼ºº¹Áõ
  • acute anxiety neurosis
    ±Þ¼ººÒ¾È½Å°æÁõ
  • acute brain syndrome
    ±Þ¼º³úÁõÈıº
  • acute catarrhal laryngitis
    ±Þ¼ºÄ«Å¸¸£Èĵο°
  • acute confusional state
    ±Þ¼ºÈ¥µ·»óÅÂ
  • acute delusional psychosis
    ±Þ¼º¸Á»óÁ¤½Åº´
  • acute disseminated encephalitis
    ±Þ¼ºÆÄÁ¾³ú¿°
  • acute fulminating meningococcemia
    ±Þ¼ºÀü°Ý¼ö¸·¾Ë±ÕÇ÷Áõ
  • acute hemolytic transfusion reaction
    ±Þ¼º¿ëÇ÷¼öÇ÷¹ÝÀÀ
  • acute idiopathic polyneuritis
    ±Þ¼ºÆ¯¹ß´Ù¹ß½Å°æ¿°, ±Þ¼ºÆ¯¹ß¿©·¯½Å°æ¿°
  • acute infectious disease
    ±Þ¼º°¨¿°º´
  • acute intermittent porphyria
    ±Þ¼º°£ÇæÆ÷¸£ÇǸ°Áõ
  • acute lichenoid pityriasis
    ±Þ¼ºÅ¼±¸ð¾çÀܺñ´ÃÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
  • NK cell [=natural killer cell]
    ÀÚ¿¬»ì»ó¼¼Æ÷
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • quiescent cell, Q cell
    Á¤Áö¼¼Æ÷
  • B type virus particle
    BÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • B type virus particle
    BÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • C type particle
    CÇüÀÔÀÚ
  • C-type particle
    CÇü ÀÔÀÚ (·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ)
  • C-type virus particle
    CÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute megakaryoblastic leukaemia
    ±Þ¼º°Å´ë¸ð±¸¼º¹éÇ÷º´
  • leukemia =leukaemia
    ¹éÇ÷º´.
  • leukemia =leukaemia
    ¹éÇ÷º´
  • chief cell type i glomus cell
    °ú¸³¼¼Æ÷
  • supporting cell [type ii glomus cell]
    ¹öÆÀ¼¼Æ÷
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • foreign body-type giant cell
    À̹°Çü °Å´ë¼¼Æ÷(¡­ËÝÓÞá¬øà)
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
  • langhans-type giant cell
    ¶û±×Çѽº°Å´ë¼¼Æ÷, Langerhans °Å´ë¼¼Æ÷(¡­ËÝÓÞá¬øà)
  • sickle cell type
    °â»óÀûÇ÷±¸Çü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷(Á¦1Çü»ç±¸¼¼Æ÷)
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Type II hair cell
    ¿øÁÖÅм¼Æ÷
    [¿¾ ¿ë¾î] ÀüÆÄ¿¬Á¢¼¼Æ÷
  • Type I hair cell
    Á¶·Õ¹ÚÅм¼Æ÷
    [¿¾ ¿ë¾î] ¹è»ó¿¬Á¢¼¼Æ÷
  • Regular type
    ±ÔÄ¢Çü
    [¿¾ ¿ë¾î] ±ÔĢġ¹Ð°áÇÕÁ¶Á÷
  • Muscular type of artery
    ±ÙÀ°Çüµ¿¸Æ
    [¿¾ ¿ë¾î] ±ÙÇüµ¿¸Æ
  • Muscular type of lymphatic vessel
    ±ÙÀ°Çü¸²ÇÁ°ü
    [¿¾ ¿ë¾î] ±ÙÇüÀӯİü
  • Muscular type of vein
    ±ÙÀ°ÇüÁ¤¸Æ
    [¿¾ ¿ë¾î] ±ÙÇüÁ¤¸Æ
  • Type B spermatogonium
    ´ÊÁ¤Á¶¼¼Æ÷
    [¿¾ ¿ë¾î] BÁ¤Á¶¼¼Æ÷
  • Anovulatory type
    ¹«¹è¶õÇü
    [¿¾ ¿ë¾î] ¹«¹è¶õÇü
  • Ovulatory type
    ¹è¶õÇü
    [¿¾ ¿ë¾î] ¹è¶õÇü
  • Irregular type
    ºÒ±ÔÄ¢Çü
    [¿¾ ¿ë¾î] ºÒ±ÔĢġ¹Ð°áÇÕÁ¶Á÷
  • Calcified hypertrophic type
    ¼®È¸È­ºñ´ëÇü
    [¿¾ ¿ë¾î] ¼®È¸È­ºñ´ëÇü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymyarian type
    ´Ù±ÙÀ°Çü
  • type specimen
    ±âÁØÇ¥º»
  • excretory cell
    ¹è¼³¼¼Æ÷
  • flame cell
    ºÒ²É¼¼Æ÷
  • G cell G
    ¼¼Æ÷
  • germ cell
    ¹è¼¼Æ÷
  • interstitial plasma cell pneumonia
    °£Áú¼ºÇüÁú¼¼Æ÷Æó¿°
  • nurse cell
    º¸¸ð¼¼Æ÷
  • renette cell
    ¹è¼³¼¼Æ÷
  • tegumental cell
    Ç¥ÇǼ¼Æ÷
  • vitelline cell
    ³­È²¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute porphyria
    ±Þ¼º(Ðáàõ) Æ÷¸£ÇǸ°Áõ (ñø)
  • acute serum
    ±Þä Ç÷û(Ðáóõúìôè)
  • acute test
    ´Ü·® µ¶¼º½ÃÇè (Ó¤ÕáÔ¸àõãËúÐ)
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • C-type particles
    C-Çü(û¡) ÀÔÀÚ(Ø£í­)
  • C-type virus
    "C-Çü(û¡) ¹ÙÀÌ·¯½º, (ÔÒ) C-type particles"
  • dehydrogenase-type mechanism
    µðÇÏÀ̵å·ÎÀú³×À̽ºÇü(úþ) ±âÀü(Ѧï®)
  • delayed-type hypersensitivity
    Áö¿¬Çü °ú¹ÎÁõ(òÀæÅû¡Î¦ÚÂñø)
  • immediate-type hypersensitivity
    Áï½ÃÇü °ú¹ÎÁõ(ñíãÁúþΦÚÂñø)
  • L-type structure
    L-Çü(úþ)±¸Á¶(ϰðã)
  • mixed-type inhibitor
    È¥ÇÕÇü ÀúÇØÁ¦(ûèùêúþîÁúªð¥)
  • plant-type ferredoxin
    ½Ä¹°Çü(ãÕÚªû¡) Æä·¹µ¶½Å
  • plaque-type mutant
    ÇöóÅ©Çü(û¡) º¯ÀÌü(ܨì¶ô÷)
  • transaminase-type mechanism
    Æ®¶õ½º¾Æ¹Ì³×À̽ºÇü (úþ) ±âÀü(Ѧï®)
  • type A hepatitis
    AÇü(úþ) °£¿°(ÊÜæú)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute
    ±Þ¼º, ¿¹¸®ÇÑ
  • acute abdomen
    ±Þ¼ºº¹Áõ
  • acute angle
    ¿¹°¢
  • acute stage
    ±Þ¼º±â
  • bell type
    Á¾¸ð¾ç, Á¾Çü
  • intracanalicular type
    ¼Ò°ü³»Çü
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´ÜX¼±ÀåÄ¡
  • onion-skin type
    ¾çÆÄ²®Áú¸ð¾ç
  • phased linear array type
    À§»óÂ÷¼±Çü¹è¿­½Ä
  • RF coil type
    °íÁÖÆÄÄÚÀÏÀ¯Çü
  • split electrode type probe
    ºÐÇÒÀü±ØÅ½ÃËÀÚ
  • acinar cell
    Æ÷»ó¼¼Æ÷
  • air cell
    ÇԱ⵿
  • alveolar cell carcinoma
    ÆóÆ÷¼¼Æ÷¾ÏÁ¾
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾ÏÁ¾
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
PMD Progressive Muscular Dystrophy; ÁøÇ༺ ±ÙÀÌ¿µ¾çÁõ
  Types of PMD(Progressive Muscular Dystroph...
AML Acute Myelogenous Leukemia
  Morphologic Classification(FABºÐ·ù)
   &n...
TAPVR Total Anomalous Pulmonary Venous Return
  = TAPVC
  4 Types of TAPVR
&...
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BCP ALL B-cell precursor acute lymphoblastic leukaemia
HTLV1 Human T cell Leukaemia Virus Type 1
HTLV-I Human T cell leukaemia virus type I
HTLV-III Human T-cell leukaemia virus type III
ALL Acute Lymphocytic Leukaemia
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • C95.0
    Acute leukaemia of unspecified cell type
    »ó¼¼ºÒ¸í ¼¼Æ÷ÇüÀÇ ±Þ¼º ¹éÇ÷º´
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • unspecified
    ºñƯÀ̼º
    ´Ù¸¥ °ÍÇÏ°í¸¸ Ưº°È÷ °áÇÕÀ» ÇÑ´ÙµçÁö ¹ÝÀÀÇϴ ƯÀ̼ºÀÌ ¾ø´Â.
  • acute and late normal tissue effects£¨Á¤»ó Á¶Á÷ ±Þ¼º ¿µÇ⣩

    acute angle

    ¿¹°¢
    Á÷°¢º¸´Ù ÀÛÀº °¢.
  • acute appendicitis£¨±Þ¼º Ãæ¼ö¿°£©

    acute arthritis

    ±Þ¼º °üÀý¿°
    ¿°Áõ°ú °¨¿°°ú ¿Ü»ó¿¡ ÀÇÇÏ¿© µ¿Åë, ¹ß¿­, ¹ßÀû, Á¾Ã¢ÀÌ ½ÉÇÑ °üÀý¿°.
  • acute mixed-lineage leukmia£¨±Þ¼º È¥ÇÕ-Á÷°è¼º ¹éÇ÷º´£©

    acute monocytic leukemia

    ±Þ¼º ´Ü±¸ ¹éÇ÷º´, ±Þ¼º ´Ü±¸¼º ¹éÇ÷º´
    ±Þ¼º ¹éÇ÷º´ÀÇ ÀÏÁ¾À̰í À¯¾à´Ü±¸°¡ ¹éÇ÷º´È­ÇÑ °ÍÀÌ´Ù. °ñ¼ö¿¡¼­ °ú¸³±¸°èÀÇ À¯¾à¼¼Æ÷¿Í ´Ü±¸°èÀÇ À¯¾à¼¼Æ÷°¡ È¥ÀçÇÏ´Â ¼ö°¡ ÀÖ°í ÀÌ °æ¿ì¿¡´Â ±Þ¼º °ñ¼ö´Ü±¸¼º ¹éÇ÷º´À̶ó°í ÇÑ´Ù.
  • epidermoid type cell
    À¯Ç¥ÇÇ ¼¼Æ÷
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • spindle cell type
    ¹æÃß ¼¼Æ÷Çü
  • clear cell basal cell carcinoma
    Åõ¸í ¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
  • abortive type
    ºÎÀüÇü
  • adenoid type
    ¼±¾ç
  • Bamberger's type
    ¸¸¼º ´Ù¹ß¼º À帷¿°
  • bilateral type
    ¾çÃøÇü
  • blood type
    Ç÷¾×Çü
  • body type
    üÇü
    ¸öÀÇ »ý±è»ý±è.
  • brush type vessel arrangement
    ¼Ö ¸ð¾çÀÇ Ç÷°ü ¹è¿­
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
acute granulocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
Origin: Gr. Haima = blood
(27 Sep 1997)
acute leukaemia <haematology> A rapidly progressive cancer of the blood of sudden onset and characterised by the uncontrolled proliferation of immature blood cells which take over the bone marrow and spill into the blood stream. If left untreated is fatal within a few weeks or months.
See: acute lymphoblastic leukaemia, acute myeloid leukaemia.
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphoblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting the type of white blood cell known as lymphocytes. Approximately 650 new cases are diagnosed every year in the UK and it is the most common form of childhood leukaemia.
Acronym: ALL
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphocytic leukaemia <radiology> 95% of cases of leukaemia in children, bone changes in 50-70% of kids (vs. 10% in adults); seen as early as 1 month after onset of symptoms, wrists and knees most commonly affected, bony defects: metaphyseal radiolucent bands! (similar findings in scurvy, JRA, syphilis), osteolytic lesions, periosteal reaction, osteosclerosis
(12 Dec 1998)
acute monocytic leukaemia <haematology> The most common translocation in this disorder of poorly differentiated monocytic cells involves chromosome region 11q in a large percentage of cases.
The translocation involves a cellular oncogene, c-ets which is mapped to the 11q23-24 region. The most common translocations reported are t(6;11), t(9;11), t(11;17) and t(11;19), of which t(9;11) (p21-22;q23) is by far the most frequently detected and implicated in acute myeloid leukaemia. The cells express CD14 surface antigen, which is diagnostic of monocytic cells.
Acronym: AML
Classification: FAB M5
(07 Apr 1998)
acute myeloblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myelogenous leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myeloid leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
acute promyelocytic leukaemia Leukaemia presenting as a severe bleeding disorder, with infiltration of the bone marrow by abnormal promyelocytes and myelocytes, a low plasma fibrinogen, and defective coagulation.
(05 Mar 2000)
common acute lymphoblastic leukaemia <haematology, oncology> A sub-type of acute lymphoblastic leukaemia affecting cells early in the B lymphocyte lineage which accounts for about 80% of all acute lymphoblastic leukaemia.
Origin: Gr. Haima = blood
(13 Nov 1997)
leukaemia, erythroblastic, acute A myeloproliferative disorder characterised by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.
(12 Dec 1998)
leukaemia, megakaryocytic, acute Nonlymphocytic leukaemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. Myelofibrosis or increased bone marrow reticulin is common.
(12 Dec 1998)
leukaemia, myelocytic, acute Progressive, malignant disease of the myeloid tissue in which the granular, polymorphonuclear leukocytes and their precursors predominate.
(12 Dec 1998)
leukaemia, nonlymphocytic, acute Acute leukaemia distinguished from acute lymphocytic leukaemia (all) by the morphology of the marrow and blood leukaemic cells. Cytoplasmic granules are usually present and the nucleus is usually large and irregular. Anll is more common in adults than all and occurs at any age.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukaemia
    ¹éÇ÷º´
  • unspecified
    Ư±â
  • acute
    ³¯Ä«·Î¿î; °Ý·ÄÇÑ
  • acute
    ³¯Ä«·Î¿î;»ÏÁ·ÇÑ;¿¹¹ÎÇÑ;ºóÆ´¾ø´Â;°Ý·ÄÇÑ;±Þ¼ºÀÇ
  • type
    Çü,ŸÀÌÇÁ,ÀüÇü,ȰÀÚ,ÀÚü
  • C-type virus
    CÇü ¹ÙÀÌ·¯½º(¹ß¾Ï¼ºÀ¸·Î ¿©°ÜÁö°í ÀÖÀ½)
  • Gothic type
    °íµñ ȰÀÚü
  • Moon type
    (¿µ±¹ÀÎ °í¾ÈÀÚ À̸§¿¡¼­)¹®Å¸ÀÌÇÁ(¹®ÀÚ ½ÀµæÈÄÀÇ ½Ç¸íÀÚ¸¦ À§ÇÑ µµµå¶óÁø ¹®ÀÚÀÇ ¼­Ã¼,Àμâ¹ý)
  • Moon type
    ¸ÍÀοëÀÇ ¹®½Ä¼±ÀÚ(¿µ±¹ÀÎ W,Moon ¹ß¸í)
  • Roman letters(type)
    ·Î¸¸Ã¼(ȰÀÚ)
  • character type
    ¼º°Ý À¯Çü
  • cold type
    ÄݵåŸÀÌÇÁ(»çÁø.½ÄÀÚµî ȰÀÚ ÁÖÁ¶¸¦ ÇÏÁö ¾Ê´Â ½ÄÀÚ)
  • cold type system
    Äݵå ŸÀÌÇÁ ½Ã½ºÅÛ(³³È°ÀÚ³ª ¿­À» »ç¿ëÇÏÁö ¾Ê°í Çʸ§À» ÁÖü·ÎÇÑ »ç½ÄÈ­¿¡ ÀÇÇÑ Àμ⠰øÁ¤
  • condensed type
    °¡´Ã°í ±ä ȰÀÚ
  • display type
    Ç¥Á¦;±¤°í¿ëÀÇ ´ëÇü ȰÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á